

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司

Tianjin TEDA Biomedical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 8189)

**(1) RESIGNATION OF DIRECTOR
AND
(2) PROPOSED APPOINTMENT OF DIRECTOR**

(1) RESIGNATION OF DIRECTOR

The Company announced that the Board has accepted the resignation of Mr. Liu Renmu, an executive Director with effect from 20 September 2018.

(2) PROPOSED APPOINTMENT OF DIRECTOR

The Board proposed to appoint Mr. He Xin as an executive Director for a term commencing on the date of approval by the Shareholders and expiring on 31 December 2019.

Such proposed appointment is subject to the approval of the Shareholders at the EGM by way of ordinary resolution. A notice of the EGM, containing the details of the relevant resolutions, will be despatched to the Shareholders as soon as practicable.

(1) RESIGNATION OF DIRECTOR

Mr. Liu Renmu (“**Mr. Liu**”) tendered a written notice to resign as an executive Director of the Company due to his busy schedule in other business which makes him no longer possible to spend sufficient time on the business of the Company.

Mr. Liu has confirmed that he has no disagreement with the Board and there are no other matters that should be brought to the attention of the Shareholders or the Stock Exchange in relation to his resignation.

The Board would like to express its sincere gratitude to Mr. Liu for his valuable contributions to the Company during his tenure of service.

(2) PROPOSED APPOINTMENT OF DIRECTOR

Due to the resignation of Mr. Liu as aforesaid, the Board proposes to appoint Mr. He Xin (“**Mr. He**”) as an executive Director for a term commencing on the date of approval by the Shareholders at the EGM and expiring on 31 December 2019.

PARTICULARS OF THE PROPOSED DIRECTOR

General Information

He Xin (何昕), male, aged 48, postgraduate, graduated from Beijing Jiaotong University majoring in Mechanical Engineering. From July 1992 to June 1994, he served as a business manager of the export department of China Railway Import and Export Company* under the Ministry of Railway (鐵道部中鐵進出口公司). From June 1994 to May 2005, he worked as a secretary of the administrative department of Shenzhen Golden Century Development Company Limited* (深圳金世紀發展有限公司). From May 2005 to September 2009, he served as an investment manager of the international department of China Merchants Securities Company Limited. From September 2010 to March 2014, he held a position as a vice president of Beijing Yingguxinye Investment Co., Ltd. From March 2014 to August 2016, he held positions as a director and a general manager of Ningxia Yinggu Industry Company Limited (寧夏盈谷實業股份有限公司). From August 2016 to present, he has been serving as a general manager of Beijing Yingguxinye Investment Co., Ltd.

(i) *The Emolument of the Director*

The proposed emolument of Mr. He is RMB40,000 per annum during his term of service which will be paid in proportion to the actual length of service starting from the date of appointment.

The proposed emolument of Mr. He is determined on the basis of prevailing market rate, scope of work, level of involvement, experience, seniority and the recommendation of the remuneration committee of the Company.

(ii) *Service Agreement of the proposed Director*

Mr. He will enter into a service agreement with the Company after the proposed ordinary resolutions regarding his appointment being passed at the EGM. The newly appointed executive Director will be for a term commencing on the date of approval by Shareholders at the EGM and expiring on 31 December 2019.

Save as disclosed above, Mr. He does not hold any other position with the Company or other members of the Group nor does he has any relationship with any other directors, supervisor, senior management, substantial shareholders or controlling shareholders of the Company or any of his associates (as defined in the GEM Listing Rules).

Save as disclosed above, Mr. He does not hold any shares, underlying shares or debentures of the Company and its associated corporations which are required to be disclosed under Part XV of the SFO.

In addition, Mr. He does not hold any position in other companies listed on the Stock Exchange or any other securities market for the last three years and do not have any other major appointments or professional qualifications.

The Board is not aware of any other matter which has to be brought to the attention of holders of securities of the Company in respect of the proposed change of Director nor is there any other information required to be disclosed pursuant to the requirements as set out in Rule 17.50(2) of the GEM Listing Rules.

EXTRAORDINARY GENERAL MEETING

According to the Articles of Association of the Company, the proposed appointment of Mr. He is subject to the approval by the Shareholders by way of ordinary resolutions at EGM.

Notice for convening the EGM containing details of the relevant resolutions will be dispatched to the Shareholders as soon as practicable.

DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context requires otherwise.

“Articles of Associations”	the articles of association adopted by the Company on 25 May 2002 (as amended from time to time)
“Board”	the board of Directors (including the independent non-executive directors)
“Company”	天津泰達生物醫學工程股份有限公司 (Tianjin TEDA Biomedical Engineering Company Limited), a joint stock company established in the PRC with limited liability on 8 September 2000 whose H shares are listed and traded on GEM (Stock Code: 8189)
“Director(s)”	director(s) of the Company
“EGM”	the extraordinary general meeting of the Company to be convened
“GEM”	GEM of the Stock Exchange
“GEM Listing Rules”	the Rules Governing the Listing of Securities on GEM
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“PRC”	the People’s Republic of China, which for the purpose of this announcement, exclude Hong Kong, the Macau Special Administrative Region and Taiwan

“RMB”	Renminbi, the lawful currency of the PRC
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong)
“Shareholder(s)”	shareholder(s) of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
21 September 2018

As at the date of this announcement, the executive Directors of the Company are Sun Li and Hao Zhihui; the non-executive Directors of the Company are Cao Aixin and Li Ximing; the independent non-executive Directors of the Company are Li Xudong, Wang Yongkang and Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at www.hkgem.com on the “Latest Company Announcements” page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.